Høgåsen K, Mollnes T E, Harboe M, Götze O, Hammer H B, Oppermann M
Institute of Immunology and Rheumatology, National Hospital, University of Oslo, Norway.
J Rheumatol. 1995 Jan;22(1):24-8.
To investigate terminal complement activation and lysis inhibitors in rheumatoid arthritis (RA).
C5a, vitronectin and clusterin were quantitated by enzyme immunoassays in plasma and synovial fluid (SF) in RA (n = 30) and osteoarthritis (OA) (n = 11).
In RA the concentration of C5a was 3-fold increased in plasma (21.9 vs 7.2 micrograms/l) and 5-fold increased in SF (7.8 vs 1.7 micrograms/l) compared to OA. The SF/plasma ratios for C5a, vitronectin and clusterin were 0.35, 0.36 and 0.23, respectively, not significantly different in the 2 diseases.
SF terminal pathway activation in RA combined with low local levels of lysis inhibitors might allow lytic or sublytic attacks on local cells, resulting in inflammation and cell damage.
研究类风湿关节炎（RA）中的终末补体激活及溶解抑制因子。
采用酶免疫分析法对30例RA患者和11例骨关节炎（OA）患者的血浆及滑膜液（SF）中的C5a、玻连蛋白和簇集素进行定量分析。
与OA相比，RA患者血浆中C5a浓度升高3倍（21.9对7.2微克/升），SF中升高5倍（7.8对1.7微克/升）。C5a、玻连蛋白和簇集素的SF/血浆比值分别为0.35、0.36和0.23，两种疾病之间无显著差异。
RA患者SF中的终末途径激活与局部溶解抑制因子水平较低相结合，可能导致对局部细胞的溶解或亚溶解攻击，从而引发炎症和细胞损伤。
